Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments

A technology of taurochenodeoxycholic acid and glucocorticoid, which is applied in the directions of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulas, etc., can solve the problem of wound healing, adverse effects of drug users' recovery, rebound phenomenon, etc. question

Inactive Publication Date: 2011-09-14
SHANDONG AGRICULTURAL UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, glucocorticoid drugs also have adverse reactions such as inducing or aggravating infection, rebound phenomenon, and affecting wound healing.
But so far, there is no safe, effective and comprehensive anti-glucocorticoid drug adverse reaction drug, can only rely on a single drug to treat different adverse reactions, which has many adverse effects on the recovery of drug users

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments
  • Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments
  • Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] During the experiment, they were divided into normal group, model group and drug administration group, each with 10 mice. The normal group was only fed with distilled water; the model group was injected intraperitoneally with 80 mg / kg dexamethasone for 7 consecutive days to prepare the mouse model of adrenal suppression caused by glucocorticoids; the administration group was prepared in the model After completion of the administration, the dose of TCDCA in the administration group was 0.1 g / kg, and the route of administration was intragastric administration, once a day, for 7 consecutive days. The mice were dissected in the normal group, the model group and the middle-dose administration group, especially the adrenal gland was observed, and the results of the anatomical changes of the adrenal gland were found in the attached figure 1 And attached Figure 5 shown. It can be seen that, compared with the administration group, the model group showed symptoms of congestion...

Embodiment 2

[0032]During the experiment, they were divided into normal group, model group and drug administration group, each with 10 mice. The normal group was only fed with distilled water; the model group was injected intraperitoneally with 80 mg / kg dexamethasone for 7 consecutive days to prepare the mouse model of adrenal suppression caused by glucocorticoids; the administration group was prepared in the model After completion of the administration, the dose of TCDCA in the administration group was 0.1 g / kg, and the route of administration was intragastric administration, once a day, for 7 consecutive days. HE staining of paraffin sections was used to evaluate the influence of TCDCA on the pathological changes of the adrenal gland, and the results are shown in the appendix figure 2 And attached Figure 6 shown. In the model group, the epithelial cells of the adrenal ducts had granular degeneration, decreased in number, and congestion of small blood vessels in the interstitium of th...

Embodiment 3

[0034] During the experiment, they were divided into normal group, model group and drug administration group, each with 10 mice. The normal group was only fed with distilled water; the model group was injected intraperitoneally with 80 mg / kg dexamethasone for 7 consecutive days to prepare the mouse model of adrenal suppression caused by glucocorticoids; the administration group was prepared in the model After completion of the administration, the dose of TCDCA in the administration group was 0.1 g / kg, and the route of administration was intragastric administration, once a day, for 7 consecutive days. TUNEL method was used to detect the effect of TCDCA on the apoptosis of adrenal gland cells. The tissue sections were observed and photographed under a 400-fold optical microscope. Dark brown cells were apoptotic cells, and light blue cells were normal cells. Three consecutive fields of view were selected in the adrenal cortex fascicularis, and the number of stained cells and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of taurochenodeoxycholic, and particularly relates to novel application of the taurochenodeoxycholic acid in treating adverse reactions of glucocorticoid medicaments. Through studying on the taurochenodeoxycholic acid, the inventor discovers that the taurochenodeoxycholic acid can resist apoptosis of suprarenal gland cells and promote multiplication of adrenal cortex stem cells so as to recover the hypothalamic-pituitary-adrenal axis inhibition caused by the glucocorticoid medicaments, promotes osteoblast to secrete osteocalcin and improve the reduced bone mineral density so as to recover osteoporosis caused by the glucocorticoid medicaments, and can reinforce the mucosal immunity function and promote multiplication of small intestine stem cells; therefore, the taurochenodeoxycholic acid can be directly administrated or made into various preparations or mixtures for preventing and treating adverse reactions caused by the glucocorticoid medicaments.

Description

technical field [0001] The invention relates to a new application of taurochenodeoxycholic acid, in particular to a new application of taurochenodeoxycholic acid for preventing and treating adverse reactions of glucocorticoid drugs. Background technique [0002] Taurochenodeoxycholic Acid (TCDCA) is a conjugated bile acid mainly present in the bile of chickens, ducks, geese, cattle, sheep, snakes and other animals. Its chemical name is 3α, 7α-dihydroxy-5β-24-cholanoyl-N-taurine, and its structural formula is as follows: [0003] [0004] It is an odorless, white powder, extremely bitter acidic compound formed by combining taurine (Tau) and chenodeoxycholic acid (CDCA). The molecular formula is C 23 (OH) 2 h 37 CONHCH 2 CH 2 SO 3 H, the relative molecular mass is 499.69. As a main component of bile, TCDCA has the characteristics of wide range of drug sources, safety and efficacy. Current studies have found that TCDCA has anti-inflammatory (Li Peifeng, Cao Jinshan, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P19/10A61P1/04
Inventor 石有斐李金莲王丛丛李培锋成子强
Owner SHANDONG AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap